Phase II Trial of Motexafin Gadolinium for Treatment of Metastatic Renal Cell Carcinoma
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Clinical response rate (CP, PR) to MGd in patients with confirmed progressive RCC (renal cell carcinoma)
Robert J Amato, D.O.
Methodist Hospital Genitourinary Oncology
United States: Food and Drug Administration
|Methodist Hospital||Houston, Texas 77030|